Literature DB >> 33144678

IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.

Li-Zong Rao1,2, Yi Wang2, Lei Zhang2, Guorao Wu2, Lu Zhang2, Fa-Xi Wang2, Long-Min Chen2, Fei Sun2, Song Jia2, Shu Zhang2, Qilin Yu2, Jiang-Hong Wei3, Hui-Ren Lei3, Ting Yuan2,3, Jinxiu Li4, Xingxu Huang5, Bin Cheng6, Jianping Zhao2, Yongjian Xu2, Bi-Wen Mo7, Cong-Yi Wang8, Huilan Zhang9.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common type of idiopathic interstitial pneumonia and has one of the poorest prognosis. However, the molecular mechanisms underlying IPF progression remain largely unknown. In this study, we determined that IL-24, an IL-20 subfamily cytokine member, was increased both in the serum of IPF patients and the bronchoalveolar lavage fluid (BALF) of mice following bleomycin (BLM)-induced pulmonary fibrosis. As a result, IL-24 deficiency protected mice from BLM-induced lung injury and fibrosis. Specifically, loss of IL-24 significantly attenuated transforming growth factor β1 (TGF-β1) production and reduced M2 macrophage infiltration in the lung of BLM-induced mice. Mechanistically, IL-24 alone did not show a perceptible impact on the induction of M2 macrophages, but it synergized with IL-4 to promote M2 program in macrophages. IL-24 suppressed IL-4-induced expression of suppressor of cytokine signaling 1 (SOCS1) and SOCS3, through which it enhanced signal transducer and activator of transcription 6/peroxisome proliferator-activated receptor gamma (STAT6/PPARγ) signaling, thereby promoting IL-4-induced production of M2 macrophages. Collectively, our data support that IL-24 synergizes with IL-4 to promote macrophage M2 program contributing to the development of pulmonary fibrosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33144678      PMCID: PMC8027679          DOI: 10.1038/s41418-020-00650-6

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  44 in total

Review 1.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

2.  Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction.

Authors:  Dmitri V Pechkovsky; Antje Prasse; Florian Kollert; Kathrin M Y Engel; Jan Dentler; Werner Luttmann; Karlheinz Friedrich; Joachim Müller-Quernheim; Gernot Zissel
Journal:  Clin Immunol       Date:  2010-07-31       Impact factor: 3.969

Review 3.  Macrophages in Tissue Repair, Regeneration, and Fibrosis.

Authors:  Thomas A Wynn; Kevin M Vannella
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

4.  Cytokine induction of interleukin-24 in human peripheral blood mononuclear cells.

Authors:  Nancy J Poindexter; Eugene T Walch; Sunil Chada; Elizabeth A Grimm
Journal:  J Leukoc Biol       Date:  2005-07-06       Impact factor: 4.962

Review 5.  Idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Harold R Collard; Mark G Jones
Journal:  Lancet       Date:  2017-03-30       Impact factor: 79.321

6.  Interleukin-24 and its receptors.

Authors:  Mai Wang; Peng Liang
Journal:  Immunology       Date:  2005-02       Impact factor: 7.397

7.  Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada.

Authors:  Robert B Hopkins; Natasha Burke; Charlene Fell; Genevieve Dion; Martin Kolb
Journal:  Eur Respir J       Date:  2016-05-26       Impact factor: 16.671

8.  Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome.

Authors:  Lisa R Young; Peter M Gulleman; Chelsi W Short; Harikrishna Tanjore; Taylor Sherrill; Aidong Qi; Andrew P McBride; Rinat Zaynagetdinov; John T Benjamin; William E Lawson; Sergey V Novitskiy; Timothy S Blackwell
Journal:  JCI Insight       Date:  2016-10-20

Review 9.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis.

Authors:  Brett Ley; Harold R Collard; Talmadge E King
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

10.  Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes.

Authors:  Z Toossi; C S Hirsch; B D Hamilton; C K Knuth; M A Friedlander; E A Rich
Journal:  J Immunol       Date:  1996-05-01       Impact factor: 5.422

View more
  15 in total

1.  Ameliorative Effects of Arctigenin on Pulmonary Fibrosis Induced by Bleomycin via the Antioxidant Activity.

Authors:  Yueshang Wang; Xinpeng Li; Shiwen Pu; Xiao Wang; Lanping Guo; Lisheng Zhang; Zhen Wang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

2.  Arginine is a key player in fibroblasts during the course of IPF development.

Authors:  Yi Wang; Jianping Zhao; Huilan Zhang; Cong-Yi Wang
Journal:  Mol Ther       Date:  2021-02-26       Impact factor: 11.454

3.  Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-catenin signaling.

Authors:  Yinan Hu; Qi Wang; Jun Yu; Qing Zhou; Yanhan Deng; Juan Liu; Lei Zhang; Yongjian Xu; Weining Xiong; Yi Wang
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

Review 4.  Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.

Authors:  Qianru Mei; Zhe Liu; He Zuo; Zhenhua Yang; Jing Qu
Journal:  Front Pharmacol       Date:  2022-01-19       Impact factor: 5.810

5.  Interleukin-24 regulates mucosal remodeling in inflammatory bowel diseases.

Authors:  Anna Ónody; Apor Veres-Székely; Domonkos Pap; Réka Rokonay; Beáta Szebeni; Erna Sziksz; Franz Oswald; Gábor Veres; Áron Cseh; Attila J Szabó; Ádám Vannay
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

6.  Local administration of liposomal-based Srpx2 gene therapy reverses pulmonary fibrosis by blockading fibroblast-to-myofibroblast transition.

Authors:  Qi Wang; Juan Liu; Yinan Hu; Ting Pan; Yongjian Xu; Jun Yu; Weining Xiong; Qing Zhou; Yi Wang
Journal:  Theranostics       Date:  2021-05-13       Impact factor: 11.600

7.  Myeloid Fbxw7 Prevents Pulmonary Fibrosis by Suppressing TGF-β Production.

Authors:  Jia He; Yue Du; Gaopeng Li; Peng Xiao; Xingzheng Sun; Wenjun Song; Lihua Lai; Meng Xia; Jianhua Zhang; Qingqing Wang
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

8.  STAT6/VDR Axis Mitigates Lung Inflammatory Injury by Promoting Nrf2 Signaling Pathway.

Authors:  Youjing Yang; Qianmin Li; Shuhui Wei; Kaimiao Chu; Lian Xue; Jie Liu; Yu Ma; Shasha Tao
Journal:  Oxid Med Cell Longev       Date:  2022-01-10       Impact factor: 6.543

Review 9.  Interleukin-24 Immunobiology and Its Roles in Inflammatory Diseases.

Authors:  Yajie Zhong; Xuan Zhang; Waipo Chong
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

10.  Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway.

Authors:  Wudi Wei; Chuanyi Ning; Jiegang Huang; Gang Wang; Jingzhen Lai; Jing Han; Jinhao He; Hong Zhang; Bingyu Liang; Yanyan Liao; Thuy Le; Qiang Luo; Zhen Li; Junjun Jiang; Li Ye; Hao Liang
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.